Beacon Therapeutics

Beacon Therapeutics is a United States based ophthalmic gene therapy company that aims to restore and enhance the sight of patients suffering from a variety of prevalent and rare retinal diseases leading to blindness. The company's scientific foundation encompasses a late-stage development candidate for treating X-linked retinitis pigmentosa (XLRP), along with two preclinical programs targeting dry age-related macular degeneration (AMD) and cone-rod dystrophy (CRD), an inherited retinal disease from the University of Oxford. The lead development candidate, AGTC-501, is a gene therapy program currently in Phase II clinical trials to treat XLRP, a disorder causing progressive vision loss primarily in boys and young men. The company's access to a target generation technology platform for identifying, screening, and researching secreted proteins in the ophthalmology space bolsters its offerings. Beacon Therapeutics is financially backed by funds from Syncona and other investors, including Oxford Science Enterprises. The company secured a £96.00M Series A investment on 12 June 2023. For more information, visit their website at www.beacontx.com.